$IRTC News

Canaccord Genuity Maintains Buy on iRhythm Holdings, Lowers Price Target to $152

B of A Securities Maintains Buy on iRhythm Holdings, Lowers Price Target to $180

iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

iRhythm Holdings, Inc. 2026 Q1 - Results - Earnings Call Presentation

Citigroup Maintains Buy on iRhythm Holdings, Raises Price Target to $157

Canaccord Genuity Maintains Buy on iRhythm Holdings, Lowers Price Target to $180

JP Morgan Maintains Overweight on iRhythm Holdings, Lowers Price Target to $175

Wells Fargo Maintains Overweight on iRhythm Holdings, Lowers Price Target to $180

Evercore ISI Group Maintains Outperform on iRhythm Holdings, Lowers Price Target to $160

Needham Maintains Buy on iRhythm Holdings, Raises Price Target to $255

iRhythm Holdings, Inc. (IRTC) Q1 2026 Earnings Call Transcript

iRhythm Holdings Inc (NASDAQ:IRTC) Beats Q1 Estimates, Raises Guidance, Shares Surge

iRhythm Holdings Raises FY2026 Sales Guidance from $870.000M-$880.000M to $875.000M-$885.000M vs $876.068M Est

iRhythm Technologies Q1 Adj. EPS $(0.35) Beats $(0.65) Estimate, Sales $199.390M Beat $194.027M Estimate

Truist Securities Maintains Buy on iRhythm Holdings, Lowers Price Target to $170

Goldman Sachs Maintains Neutral on iRhythm Holdings, Lowers Price Target to $147

Evercore ISI Group Maintains Outperform on iRhythm Holdings, Lowers Price Target to $170

Q4 Patient Monitoring Earnings Review: First Prize Goes to iRhythm (NASDAQ:IRTC)

Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story

iRhythm Holdings Appoints Jason Patten to its Board of Directors